Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 4;173(3):195-203.
doi: 10.7326/M20-1515. Epub 2020 May 15.

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review

Katherine Mackey  1 , Valerie J King  2 , Susan Gurley  2 , Michael Kiefer  2 , Erik Liederbauer  2 , Kathryn Vela  1 , Payten Sonnen  1 , Devan Kansagara  1
Affiliations

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review

Katherine Mackey et al. Ann Intern Med. .

Update in

Abstract

Background: The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in coronavirus disease 2019 (COVID-19) susceptibility, severity, and treatment is unclear.

Purpose: To evaluate, on an ongoing basis, whether use of ACEIs or ARBs either increases risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or is associated with worse COVID-19 disease outcomes, and to assess the efficacy of these medications for COVID-19 treatment.

Data sources: MEDLINE (Ovid) and Cochrane Database of Systematic Reviews from 2003 to 4 May 2020, with planned ongoing surveillance for 1 year; the World Health Organization database of COVID-19 publications and medRxiv.org through 17 April 2020; and ClinicalTrials.gov to 24 April 2020, with planned ongoing surveillance.

Study selection: Observational studies and trials in adults that examined associations and effects of ACEIs or ARBs on risk for SARS-CoV-2 infection and COVID-19 disease severity and mortality.

Data extraction: Single-reviewer abstraction confirmed by another reviewer, independent evaluation by 2 reviewers of study quality, and collective assessment of certainty of evidence.

Data synthesis: Two retrospective cohort studies found that ACEI and ARB use was not associated with a higher likelihood of receiving a positive SARS-CoV-2 test result, and 1 case-control study found no association with COVID-19 illness in a large community (moderate-certainty evidence). Fourteen observational studies, involving a total of 23 565 adults with COVID-19, showed consistent evidence that neither medication was associated with more severe COVID-19 illness (high-certainty evidence). Four registered randomized trials plan to evaluate ACEIs and ARBs for treatment of COVID-19.

Limitation: Half the studies were small and did not adjust for important confounding variables.

Conclusion: High-certainty evidence suggests that ACEI or ARB use is not associated with more severe COVID-19 disease, and moderate-certainty evidence suggests no association between use of these medications and positive SARS-CoV-2 test results among symptomatic patients. Whether these medications increase the risk for mild or asymptomatic disease or are beneficial in COVID-19 treatment remains uncertain.

Primary funding source: None. (PROSPERO: registration number pending).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
ACE2, the RAS, and SARS-CoV-2 infection. As part of the RAS, ACE2 (green) regulates the levels of angiotensin II. As the functional receptor for SARS-CoV-2, ACE2 may facilitate viral entry into cells. This figure illustrates the role of ACE2 in the RAS and how pharmacologic RAS blockade with ACEIs or ARBs (red) could theoretically increase the amount of ACE2 available for viral binding. ACE2 = angiotensin-converting enzyme 2; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; AT1 = type 1 angiotensin receptor; RAS = renin–angiotensin system; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Figure 2.
Figure 2.
Evidence search and selection based on the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) approach (as of 4 May 2020).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Watkins J. Preventing a covid-19 pandemic [Editorial]. BMJ. 2020;368:m810. [PMID: 32111649] doi:10.1136/bmj.m810. - PubMed
    1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [Letter]. Lancet Respir Med. 2020;8:e21. [PMID: 32171062] doi:10.1016/S2213-2600(20)30116-8. - PMC - PubMed
    1. Gauer R, LaRocque J. JNC 8: relaxing the standards [Editorial]. Am Fam Physician. 2014;90:449-52. [PMID: 25369620] - PubMed
    1. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S111-S134. [PMID: 31862753] doi:10.2337/dc20-S010. - PubMed
    1. Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94. [PMID: 31996437] doi:10.1128/JVI.00127-20. - PMC - PubMed

Publication types

Substances

LinkOut - more resources